Vaishali Sanchorawala MD
Professor, Hematology & Medical Oncology
Associate Director, Amyloidosis Center
72 E. Concord Street | (617) 358-4750vaishali.sanchorawala@bmc.org
vsanchor@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Amyloidosis Center
Biography
72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
Other Positions
Education
MBBS, Seth G.S. Medical College
Publications
Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Sep 22. PMID: 40981270.
Published on 9/11/2025Muchtar E, Gonzalez Bonilla H, Sanchorawala V, Gurijala N, Masri A, Davis B, Abou Ezzeddine O, Milani P, Palladini G, Cuomo M, Maurer M, Grogan M. A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis. Amyloid. 2025 Sep 11; 1-4. PMID: 40932302.
Published on 9/9/2025Parker T, Rosenthal AL, Sanchorawala V, Landau HJ, Campagnaro EL, Kapoor P, Neparidze N, Girnius SK, Hagen P, Scott EC, Hoering A, Durie BGM, Orlowski RZ. Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702). Blood. 2025 Sep 09. PMID: 40925099.
Published on 9/2/2025Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K. Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient. Br J Haematol. 2025 Sep 02. PMID: 40898649.
Published on 8/20/2025Joshi T, Prokaeva T, Gopal DM, Verma A, Sanchorawala V, Chen H, Burks E, Dasari S, McPhail ED, Staron A. Wild-Type Transthyretin Amyloidosis in the Kidneys. JACC Case Rep. 2025 Aug 20; 105132. PMID: 40833310.
Published on 7/28/2025Murakami N, Blosser CD, Webber AB, Gupta G, Singh N, Boppana S, Master S, Parasuraman R, Campagnaro EL, Java A, Sprangers B, Bhasin-Chhabra B, Lum E, Khirfan D, Alexander MP, Molnar MZ, Benes B, Thakur AK, Bumma N, Karam S, Hultcrantz M, Bridoux F, Sanchorawala V, Leung N, Landau H. Management recommendations for kidney transplantation in patients with plasma cell dyscrasia. Kidney Int. 2025 Jul 28. PMID: 40738478.
Published on 7/1/2025Hicks CW, Prokaeva T, Spencer B, Jayaraman S, Huda N, Wong S, Chen H, Sanchorawala V, Lavatelli F, Gursky O. Cryo-EM of cardiac AL-224L amyloid reveals shared features in ?6 light chain fibril folds. bioRxiv. 2025 Jul 01. PMID: 40631131.
Published on 6/17/2025Ramireddy S, Prokaeva T, Chen H, Spencer B, Wong S, Dasari S, Dao L, McPhail ED, Sanchorawala V, Mendelson L. The Amyloidosis Intersection: Dual Amyloid Types in a Single Host. Eur J Haematol. 2025 Sep; 115(3):287-298. PMID: 40526008.
Published on 5/14/2025Bart NK, Bianchi G, Cuddy SAM, Goyal P, Griffin JM, Hummel SL, Macdonald P, Maurer M, Montgomery E, Nanne MG, Orkaby AR, Sanchorawala V, Damluji AA. Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensus. JACC Adv. 2025 Jun; 4(6 Pt 1):101784. PMID: 40373524.
Published on 4/11/2025Muchtar E, Sanchorawala V, Hassan H, Hegenbart U, Schönland S, Lee HC, Qazilbash M, Kin A, Zonder J, Jacob E, Buadi F, Dispenzieri A, Dingli D, Arai S, Chin M, Chakraborty R, Lentzsch S, Magen H, Shkury E, Sarubbi C, Landau H, Gertz M. The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis. Am J Hematol. 2025 Jul; 100(7):1141-1151. PMID: 40214172.
Media Mentions
Published on 10/13/2024
New study underway in Boston for people with advanced stage of AL amyloidosis
Published on 6/27/2024
: Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/27/2024
Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/26/2024
Published on 6/26/2024
Published on 9/22/2022
There’s New Proof Crispr Can Edit Genes Inside Human Bodies
Published on 8/5/2022
Young Black Patients With AML Face Significantly Worse Outcomes
Published on 7/20/2022
Stem Cell Transplantation Shows Promise in AL Amyloidosis
Published on 7/14/2022
Published on 7/14/2022
View full list of 15 media mentions.